# README: Chunked Paper Files for AI Digital Twin PDAC Simulation

## Purpose of This README

This README is intended for Claude Opus 4 Max (1M context) processing all 10 chunked markdown files together for the purpose of assisting in the development of a **new physical AI oncology trial paper**. The source paper is:

> Kawchak, Kevin. *Accelerating FDA Compliance and Cost Efficiency of in silico Clinical Trials via AI Digital Twin Pancreatic Cancer Simulation.* Zenodo. 2025. DOI: 10.5281/zenodo.17239510

The 10 files below preserve the original paper's text verbatim. No content has been summarized or abbreviated. Images and .sty files were excluded per the chunking instructions.

---

## File Index and Descriptions

### chunk_01_title_abstract.md
**Content:** Title, author (Kevin Kawchak, ChemicalQDevice, San Diego, CA, September 30, 2025), and the full structured abstract.

**Abstract structure (all 6 subsections):**
- **Question of Interest** — The core research question: whether a bidirectional PDAC digital twin can provide credible arm-level efficacy/safety predictions (ORR, DCR, mPFS, mOS, HRs, G3+ AE, dropout) to prioritize Phase II platform-trial arms.
- **Context of Use (COU)** — Cohort-level digital twin simulates a 10-arm PDAC platform trial (~100 patients/arm, 36-month horizon, dt=1 day). Describes the model framework, data sources (MPACT, NAPOLI-1, POLO), and VVUQ test suite executed (V-01 through A-04).
- **Model Influence: Medium** — Justification for rating.
- **Consequence of Wrong Decision: Medium** — Justification for rating.
- **Model Risk: Medium** — Justification for combined risk rating per M15 and ASME V&V 40.
- **Model Impact: Medium (with a path to High)** — Justification and conditions for elevation.

**Key correlations:**
- The COU in chunk_01 directly maps to the trial configuration detailed in chunk_04 (patient archetypes, 10 arms, 36-month horizon).
- The VVUQ test IDs mentioned (V-01 through A-04) are fully defined in chunk_07.
- Model Influence/Risk ratings connect to the financial savings discussion in chunk_08 and regulatory compliance conclusion in chunk_09.
- External validation references (MPACT Arm A, NAPOLI-1 Arm G, POLO Arms J/K) are discussed quantitatively in chunk_09 (Limitations) and the arm results appear in chunk_05.

---

### chunk_02_introduction.md
**Content:** Section 1: Introduction (three paragraphs).

**Paragraph 1** — Historical context of MIDD (Model-Informed Drug Development) from the 1990s through PDUFA VI. Cites Madabushi et al. 2022 (ref: 03IntroMadabushi), Craig et al. (ref: 04IntroCraig), and Galluppi et al. (ref: 05IntroGalluppi). Identifies software disadvantages in current MIDD approaches.

**Paragraph 2** — November 2023 FDA guidance "Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions" and its application of ASME V&V 40. Cites ref: 01IntroFDA2023.

**Paragraph 3** — November 2024 "M15 General Principles for Model-Informed Drug Development" guidance. Details Appendix 1 (Question of Interest, Context of Use, Model Impact) and MIDD planning stage elements. Cites ref: 02IntroFDA2025.

**Key correlations:**
- The three regulatory frameworks cited here (ASME V&V 40, FDA 2023 Credibility guidance, M15 2024) are operationalized throughout: V&V tests in chunk_07, compliance conclusions in chunk_09.
- The software disadvantages mentioned (manual coding, black box approaches, variable selection) directly motivate the AI-assisted methods described in chunk_03.
- The M15 Appendix 1 elements (Question of Interest, COU, Model Impact) correspond exactly to the abstract structure in chunk_01.

---

### chunk_03_methods.md
**Content:** Section 2: Methods (four paragraphs plus AI model specifications).

**Paragraph 1** — Use of conversational AI to address MIDD software disadvantages; AI used to process FDA and M15 documents for test recommendations; abstract structured per Appendix 1 elements.

**Paragraph 2** — Origin of digital twin arms from prior studies (refs: 18KawchakPDAC, 19KawchakSimPDAC, 20KawchakQSPPDAC). Quad AI peer review (ChatGPT, Gemini, Opus, Grok). Protocol development using ChatGPT 5 Pro Research. Opus 4.1 generated first functional Python notebook. External validation of control arms A and G.

**Paragraph 3** — Notebook optimization iterations (Prompts 07–08). Gemini evaluation of notebooks. ASME V&V40/FDA checks. Comparison of notebooks via Gemini.

**Paragraph 4** — Prompt 12 refactoring for simplified core dynamics. Prompt 13 final EMax/EC50 user optimization. 1000 patient logs. 55 V&V 40 tests. Grok 3/4 for larger tasks. Sonnet 4.5 for LaTeX and financial dashboard. Hardware: MacOS 14.5, Chrome 139.

**AI Tool Specifications:**
- ChatGPT: OpenAI GPT-5 Deep Research + GPT-5 High Reasoning (abstract and visualizations)
- Gemini: Google Gemini 2.5 Pro via AI Studio (Temp=1, budget=32768, Top P=0.95; alt: Temp=0.2, Top P=0.95)
- Opus: Claude Opus 4.1 Extended
- Sonnet: Claude Sonnet 4.5 Extended
- Grok: xAI Grok 3 and Grok 4 Fast

**Key correlations:**
- The prior studies cited (refs 18, 19, 20) are the direct predecessors of this work; arms B/C/D/E/H/I drug combinations trace back to them.
- The 14 prompts referenced here are fully documented with their exact text in chunk_09 (Standards 1–4).
- The 55 V&V 40 tests mentioned here are defined in chunk_07 (V-01 through A-04).
- The file names listed for each prompt (e.g., B1_Final_Trial_Code.ipynb) are catalogued in the Data Availability section of chunk_09.
- The final notebook (final_g25p_...) produces the output in chunk_05.

---

### chunk_04_section_ii_table.md
**Content:** The complete "Section II: Python Digital Twin Phase II Trial Simulation" implementation table. Four major subsections rendered as markdown headers and structured lists.

**Virtual Trial Design & Population:**
- Global config: 1000 patients, 36 months, dt=1.0, seed=20260115
- 7 patient archetypes (ARCH-01 through ARCH-07) with prevalence percentages
- Biomarker assignments (gBRCA 20%, KRAS-G12C 21%, KRAS-G12D 35%, CD47-high 60%, HA-high 9%)
- Baseline parameter ranges

**Treatment Regimens & Drug Modeling:**
- 10 treatment arms (A through K, excluding F) — names, drugs, and control/experimental status
- 11 drugs with Emax, EC50, half-life values
- Dosing schedules by drug class
- Toxicity model (REGIMEN_TOXICITY dictionary, G3+ probabilities 0.036–0.054/cycle)

**Digital Twin Bidirectional System:**
- DigitalTwin class functions (CR/PR/SD/PD assessment, decision log, 1L→2L→BSC)
- PatientSimulator class functions (tumor volumes, PK/PD integration, RECIST progression)
- Tumor dynamics (Lotka-Volterra, logistic K=100, sensitive vs resistant kill rates)
- Adaptive decision triggers
- Survival modeling (base hazard=0.0012/day, BRCA ×0.25, post-progression ×5.0)

**Simulation Process & Outputs:**
- 38 cycles (1064 days) loop structure
- RECIST 1.1 response criteria
- 6 output CSV files
- Runtime: 13.12 seconds for 1000 patients × 36 months

**Key correlations:**
- The 10 arms named here produce the summary statistics output in chunk_05.
- Drug parameters (Emax, EC50, half-life) are directly tested in sensitivity analyses S-01/S-02/S-03 in chunk_07.
- Patient archetypes and their prevalences are tested in applicability analysis A-01 in chunk_07.
- The RECIST 20% threshold is tested in A-03 in chunk_07.
- The max_months=36 config is tested in A-04 in chunk_07.
- Resistance flag (40% primary) is tested in S-05 in chunk_07.
- Base hazard and BRCA multiplier are tested in S-08/S-09 in chunk_07.
- The 6 CSV output files are listed by name in the Data Availability section of chunk_09.

---

### chunk_05_results_simulation_output.md
**Content:** Section 3: Results — the complete console output of the Python digital twin simulation run. Presented verbatim as a code block.

**Content includes:**
- Cycle-by-cycle progress bar (38 cycles, showing alive patients and progression counts)
- Final alive count by cycle (1000 → 945 → 849 → ... → 27 at cycle 36)
- CSV output confirmation messages
- Complete TRIAL SUMMARY STATISTICS table for all 10 arms (A–K excluding F):
  - N, ORR%, DCR%, mPFS (HR), PFS-6, mOS (HR), OS-12, Safety G3+/Drop%
- Final simulation runtime (13.12 seconds)
- Checklist of digital twin achievements

**Key correlations:**
- These arm-level results (ORR, mPFS, mOS) are compared against published clinical trial data in the Limitations section of chunk_09 (Arm A vs MPACT, Arm G vs NAPOLI-1, Arms J/K vs POLO).
- The dt=1.0 results here appear as the bottom table in the three-table temporal convergence series in chunk_07.
- The patient count progression (1000 → 27) corresponds to the swimmer plot data for Patient 0002 in chunk_06.
- Arm J's superior mPFS (10.3 mo) and mOS (21.5 mo) drive the Kaplan-Meier conclusion referenced in chunk_06.
- The 6 CSV file confirmations connect to the Data Availability file list in chunk_09.

---

### chunk_06_results_adaptations_km_wf.md
**Content:** Section 4: Results — Digital Twin Simulation Adaptations, with patient-level adaptation data table and Kaplan-Meier/Waterfall subsection.

**Patient Adaptation Table** (3 patients shown from 8 displayed in swimmer plot):
- Patient 0002: 13 adaptation entries (Days 28–700, Cycles 1–25) — maintained on Arm E (PR throughout), progressed Day 588 to 2L (Arm G), then BSC. Longest-lived patient.
- Patient 0008: 3 adaptation entries — started Arm C, discontinued Day 84 (Grade 3 toxicity), progressed Day 140 to Arm G.
- Patient 0208: 12 adaptation entries — started Arm C, 9 cycles SD, Grade 3 toxicity Day 252 (BSC), progressed to Arm G, second toxicity Day 364 (BSC again), then BSC until Day 644.

**Kaplan-Meier and Waterfall Plots subsection:**
- Notes that KM plot favors Arm J
- Waterfall plots: best responses for Arm C and Arm J
- Regimen occupancy: most patients on BSC over time
- Heatmap: 1st line transitions to 2nd line highlight Arm G

**Key correlations:**
- The 1L→2L→BSC transition logic driving Patient 0002's treatment history is defined in chunk_04 (DigitalTwin Class, PatientSimulator Class sections).
- Grade 3+ toxicity dropout in Patient 0008 corresponds to S-07 toxicity-dropout test in chunk_07.
- The ECOG deterioration trigger mentioned in chunk_04 is visible in Patient 0208's BSC transitions.
- The swimmer plot figures are from the final_g25p notebook outputs; the file names are in chunk_09 Data Availability.
- Arm J's favorable KM result is consistent with its mPFS=10.3 mo and mOS=21.5 mo in chunk_05, and is discussed in chunk_09 Conclusions.

---

### chunk_07_vv_tests_verification_validation.md
**Content:** The complete V&V Test Suite (Parts 1 and 2) tables plus four narrative subsections.

**V&V Test Suite Part 1 — Model Verification & Numerical Checks (V-01 through V-06):**
Each entry includes Purpose, Parameter path, Original Value, and Test Values.

**V&V Test Suite Part 1 — Model Validation & Sensitivity Analysis (S-01 through S-09):**
Each entry includes Purpose, Parameter path, Original Value, and Test Values.

**Temporal Convergence (dt) subsection:**
- Three complete 10-arm results tables at dt=0.1, dt=0.5, and dt=1.0 (all arms A–K)
- Narrative: convergence demonstrated for Arm A (mPFS 4.6/4.7, mOS 9.3/9.3 at dt=0.95/1.0)

**Model Verification & Numerical Checks subsection:**
- Narrative analysis of V-01 (dt convergence) and V-02 (seed reproducibility)
- Overall verification score: 81.9/100

**Model Validation & Sensitivity Analysis subsection:**
- Narrative analysis of S-07 (dropout-AE correlation), S-04/S-05/S-01–S-03/S-06/S-07/S-08/S-09 (radar chart), S-01/S-02 (violin plot), S-01–S-09 overall (gauge dashboard)
- Overall validation score: 85.75%

**V&V Test Suite Part 2 — Uncertainty Quantification (UQ-01 through UQ-03):**
Each entry with Purpose, Parameter, Original Value, Test Values.

**V&V Test Suite Part 2 — Applicability Assessment (A-01 through A-04):**
Each entry with Purpose, Parameter, Original Value, Test Values.

**Key correlations:**
- All parameter paths (e.g., DRUG_PARAMS['gemcitabine']['Emax'], ARCHETYPES['ARCH-01']['growth_rate']) correspond to exact variables defined in chunk_04's implementation tables.
- The dt=1.0 result table in the temporal convergence section is identical to the main results table in chunk_05.
- The pass/fail narrative ("81.9/100 for Verifications", "85.75% for Validations") is cited in chunk_09 Conclusions.
- A-01 archetype prevalence test uses the ARCH-01/ARCH-02 percentages defined in chunk_04.
- A-03 RECIST threshold 0.20 corresponds to the PatientSimulator.check_progression value in chunk_04.
- A-04 max_months=36 corresponds to the GLOBAL_CONFIG value in chunk_04.

---

### chunk_08_uq_applicability_financial.md
**Content:** Three major components: Uncertainty Quantification subsection narrative, Applicability Assessment subsection narrative, and Financial Assessments section.

**Uncertainty Quantification narrative:**
- ORR% box plot (UQ-03): 10 seeds, stochastic uncertainty quantified, per-arm variability shown
- Radar analysis (UQ-01): sigma parameter (0.2–0.8), Arm C and Arm J, mPFS/mOS impact
- PFS-6 uncertainty bands (UQ-03): min-max range across 10 seeds
- DCR waterfall limitation: high DCR values across arms indicate calibration gap; serves as baseline for future improvements

**Applicability Assessment narrative:**
- Forest plot (A-01, A-03, A-04): HR stability across population mix, RECIST threshold, and horizon tests
- Credibility summary (A-01–A-04): Population Validation, Emergent Model Behavior, Calculation Verification scores
- Note: A-02 dosing schedule data not available in the script

**Financial Assessments:**
- Reference to a financial dashboard figure (FinancialDashboard_DTwin.jpg) showing accelerated FDA cost efficiency
- Caption: "Several Aspects of the FDA MIDD Submission Process Have Been Optimized"

**Key correlations:**
- UQ-01 and UQ-03 are defined in chunk_07; this chunk provides their visual and narrative outcomes.
- A-01 through A-04 are defined in chunk_07; this chunk provides their outcomes.
- The sigma parameter tested (0.2–0.8) corresponds to the lognormal sensitivity multiplier in chunk_04 (mean=-0.2, sigma=0.4).
- The DCR calibration limitation noted here connects to the broader calibration discussion in chunk_09 Limitations.
- The financial dashboard connects to the abstract's "Model Impact: Medium (with a path to High)" claim in chunk_01 and the cost efficiency conclusions in chunk_09.

---

### chunk_09_standards_limitations_conclusions.md
**Content:** The four process standards (with all 14 prompt texts), Limitations and Future Work section, Conclusions section, Data Availability (full file list), ASME V&V 40 / FDA Standards file listing, and end matter (Acknowledgments, Ethical Disclosures, Rights and Permissions, About This Study).

**Standard 1 (Prompts 01–03):** AI Peer Review to First Digital Twin Notebook
- Quad AI code review → consolidated Top 12 list → text protocol → first Python notebook
- Full verbatim text of Prompts 01, 02, 03 with attached file lists
- Process diagram: Prior QSP Python Code → Quad AI Code Review → Prior QSP Main Paper → Consolidated Peer Review → Main Text Protocol → Digital Twin First Code

**Standard 2 (Prompts 04–07):** Parameter Optimization and External Validation
- Notebook iterations with external control arm calibration (Arms A and G)
- Full verbatim text of Prompts 04, 05, 06, 07 with specific parameter recommendations
- Process diagram: Prior DT Notebook → Prior DT Log Files → Parameter Optimization → External Validation → Notebook Comparisons → Top Current Notebook

**Standard 3 (Prompts 08–10):** Re-Optimize Baseline Characteristics, Notebook Speedup, VVUQ
- B1 settings transfer to fix_ops41, >12x speedup, VVUQ test generation
- Full verbatim text of Prompts 08, 09, 10 with ASME V&V 40 justification
- Process diagram: Prior QSP Python Code → Baseline Characteristics → Parameter Settings → Updated Notebook → Notebook Speedup → New VVUQ Code Tests

**Standard 4 (Prompts 11–14):** Model Simplification, Refactoring, and Calibrations
- Projected trial statistics vs simulation gap analysis → simplified model → final calibrated notebook → text protocol
- Full verbatim text of Prompts 11, 12, 13, 14 with PROJECTED TRIAL SUMMARY STATISTICS table
- Process diagram: Notebook Comparisons → Notebook Calibrations → Simplified Model → Notebook Refactoring → Final Summary → User Calibrations

**Limitations and Future Work:**
- Model simplifications vs advanced digital twin capabilities (no Bayesian updating, no immune compartments, no spatial heterogeneity, no EHR ingestion, no reinforcement learning)
- Detailed calibration gap analysis: Arm A (ORR 21% vs ~23%, mPFS 4.7 vs ~5.5 mo, mOS 9.3 vs ~8.5 mo), Arm G (mPFS 1.8 vs ~3.1 mo), Arms J/K vs POLO
- Missing statistical elements: no CIs, no p-values, no multiplicity control
- Future work: repeated simulations for CIs, tighter calibration, porting QSP mechanisms

**Conclusions:**
- Four key digital twin mechanisms verified: I) generates patient data, II) analyzes data, III) returns recommendations, IV) updates after treatment
- Comparison to prior QSP study (simpler but demonstrates end-to-end loop)
- Phase II "umbrella/platform" trial design context (100 patients/arm, 10 arms, BRCA/KRAS stratification)
- Compliance achievements: ASME V&V 40 and FDA Credibility guidance addressed with AI-driven efficiency
- Verification score: 81.9/100; Validation score: 85.75%

**Data Availability:** 67 numbered files across 14 prompts + final files, organized by prompt number with file type suffixes.

**ASME V&V 40 Test Inventory:** 55 tests listed with numbers (V-01 to A-04) and point values.

**Key correlations:**
- The PROJECTED TRIAL SUMMARY STATISTICS in Prompt 12 is the clinical target that the final_g25p results in chunk_05 were calibrated toward.
- The four digital twin mechanisms (I–IV) in Conclusions are implemented as the DigitalTwin and PatientSimulator classes in chunk_04.
- The calibration gaps described in Limitations directly compare to the final output in chunk_05.
- The 55 V&V tests in the file inventory correspond to the V-01 through A-04 tests defined in chunk_07.
- Standards 1–4 prompts trace the iterative development of the final notebook whose output appears in chunk_05.
- The prior QSP study (ref 20KawchakQSPPDAC) cited in Conclusions is the parent work from which arms and parameters were transferred per chunk_03.

---

### chunk_10_references_bibtex.md
**Content:** Complete BibTeX database from references.bib. All entries verbatim.

**Reference categories present:**
- AI model tools: Claude (various versions), ChatGPT/OpenAI (GPT-4o, o1, o3, o4-mini, GPT-4.5, GPT-5), Gemini (2.0, 2.5 Pro), Grok (3, 4, 4 Fast), Meta AI, DeepSeek-R1
- Kawchak prior work series (01–21): 21 sequential Zenodo/ChemRxiv/bioRxiv papers from 2024–2025 (LLMs for drug discovery → PDAC digital twin)
- GitHub repositories: 4 entries (LLMs-Pharmaceutical, DOI: 10.5281/zenodo.13273141)
- AI infrastructure: Google Colab, Visual Studio Code, Google Docs, LangChain, AutoGen, CrewAI, Databricks
- FDA regulatory guidance: 01IntroFDA2023 (ASME V&V 40 credibility), 02IntroFDA2025 (M15 MIDD)
- MIDD/clinical methodology: 03IntroMadabushi, 04IntroCraig, 05IntroGalluppi
- Oncology LLM literature: ~30 cancer/oncology-specific LLM application papers
- LLM inference and architecture: ~10 papers on LLM efficiency, context length, reasoning

**Key correlations:**
- Refs 18KawchakPDAC, 19KawchakSimPDAC, 20KawchakQSPPDAC are the three immediate predecessor PDAC papers cited throughout chunks 02, 03, and 09 (arms, parameters, VVUQ template).
- Ref 21KawchakDTwinPDAC is the current paper's own Zenodo record (cited in Data Availability and About This Study in chunk_09).
- Refs 01IntroFDA2023 and 02IntroFDA2025 underpin the entire VVUQ framework in chunk_07.
- Refs ChatGPT5DR, ChatGPT5H, Opus41, Sonnet45, Grok4Fast, Google_AI_Studio are the AI tools whose specifications appear in chunk_03 Methods.
- The cancer LLM literature (Naik, Tariq, Li, Gilbert, Kim, Park etc.) provides background context for the Introduction in chunk_02.

---

## Cross-File Correlation Summary

The 10 chunks form a linear narrative with tight parameter-level linkages:

```
chunk_01 (Abstract/COU) 
    ↕ defines research scope
chunk_02 (Introduction)
    ↕ motivates via regulatory gaps
chunk_03 (Methods)
    ↕ specifies tools and workflow → details in chunk_09 (Standards 1-4)
chunk_04 (Implementation Table)
    ↕ parameter definitions → tested in chunk_07 (V&V tests)
chunk_05 (Simulation Output)
    ↕ final arm results → compared to targets in chunk_09 (Limitations)
chunk_06 (Patient Adaptations)
    ↕ patient-level mechanisms → defined in chunk_04, visualized from chunk_05 data
chunk_07 (V&V Test Suite)
    ↕ test definitions and results → outcomes narrated in chunk_08
chunk_08 (UQ/Applicability/Financial)
    ↕ outcomes narrative → compliance claims in chunk_09 (Conclusions)
chunk_09 (Standards/Limits/Conclusions)
    ↕ full prompt history and calibration targets → all arms reference chunk_05
chunk_10 (References)
    ↕ cited throughout all 9 prior chunks
```

**For the new physical AI oncology trial paper:** The trial design parameters in chunk_04, the VVUQ framework in chunk_07, the arm performance results in chunk_05, and the regulatory compliance structure in chunks 01/02/09 collectively provide a complete template for adapting this simulation-based approach to a physical trial context. Key areas for adaptation include: replacing simulated patient data with real EHR/sensor inputs, upgrading the rule-based decision policy to reinforcement learning or MPC, adding PHI controls and deployment infrastructure, and expanding external validation to simultaneous multi-endpoint calibration across all control arms.
